Elaine M. Hylek, MD

Professor, Medicine

Elaine Hylek
801 Massachusetts Ave Crosstown Center


Expertise includes: Arterial Thrombosis; Venous Thrombosis; Atrial Fibrillation; Safety and Effectiveness of Antithrombotic Therapy.

Other Positions

  • Active Staff Privileges, Medicine, Boston Medical Center


  • University of Pittsburgh School of Medicine, MD
  • Harvard School of Public Health, MPH
  • University of Pittsburgh, MS
  • Pennsylvania State University, BS

Classes Taught


  • Published on 11/19/2018

    Hylek EM. Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle. Thromb Haemost. 2018 Dec; 118(12):2018-2019. PMID: 30453349.

    Read at: PubMed
  • Published on 11/1/2018

    Jackson LR, Kim S, Shrader P, Blanco R, Thomas L, Ezekowitz MD, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439. PMID: 30051164.

    Read at: PubMed
  • Published on 10/16/2018

    Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018 Oct 16; 138(16):1666-1676. PMID: 29871978.

    Read at: PubMed
  • Published on 10/9/2018

    Hylek EM. Apixaban for End-Stage Kidney Disease. Circulation. 2018 Oct 09; 138(15):1534-1536. PMID: 30354524.

    Read at: PubMed
  • Published on 9/18/2018

    Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. J Am Heart Assoc. 2018 Sep 18; 7(18):e008928. PMID: 30371218.

    Read at: PubMed
  • Published on 9/12/2018

    Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2018 Sep 12. PMID: 30209126.

    Read at: PubMed
  • Published on 8/28/2018

    O'Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, Kowey PR, Singer DE, Ezekowitz MD, Naccarelli GV, Ansell JE, Chan PS, Mahaffey KW, Go AS, Freeman JV, Reiffel JA, Peterson ED, Piccini JP, Hylek EM. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation. 2018 Aug 28; 138(9):889-897. PMID: 29678813.

    Read at: PubMed
  • Published on 8/21/2018

    Jackson LR, Kim S, Fonarow GC, Freeman JV, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Singer D, Thomas L, Blanco R, Peterson ED, Piccini JP. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries. J Am Heart Assoc. 2018 Aug 21; 7(16):e008764. PMID: 30369317.

    Read at: PubMed
  • Published on 8/14/2018

    Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018 Aug 14; 72(7):721-733. PMID: 30092948.

    Read at: PubMed
  • Published on 8/1/2018

    Ko D, Razouki Z, Otis J, Marulanda-LondoƱo E, Hylek EM. Anticoagulation reversal in vitamin K antagonist-associated intracerebral hemorrhage: a systematic review. J Thromb Thrombolysis. 2018 Aug; 46(2):227-237. PMID: 29687299.

    Read at: PubMed

View 229 more publications: View full profile at BUMC

View all profiles